Why do obese patients with heart failure with reduced ejection fraction have better outcomes from pharmacological treatments? Letter regarding the article 'Use of and association between heart failure pharmacological treatments and outcomes in obese versus non-obese patients with heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry'

Affiliations

¹ Department of Pharmacy, The Affiliated Yixing Hospital of Jiangsu University, Wuxi, China.
² Department of Cardiology, The Affiliated Yixing Hospital of Jiangsu University, Wuxi, China.
³ Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, China.

Free article

Comment

Wu Bo et al. Eur J Heart Fail. 2023 Jun.

Free article

. 2023 Jun;25(6):922.

doi: 10.1002/ejhf.2865. Epub 2023 Apr 23.

¹ Department of Pharmacy, The Affiliated Yixing Hospital of Jiangsu University, Wuxi, China.
² Department of Cardiology, The Affiliated Yixing Hospital of Jiangsu University, Wuxi, China.
³ Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, China.

No abstract available

Comment in

Reply to: 'Why do obese patients with heart failure with reduced ejection fraction have better outcomes from pharmacological treatments?'.
Cappelletto C, Stolfo D, Savarese G. Cappelletto C, et al. Eur J Heart Fail. 2023 Jun;25(6):922-923. doi: 10.1002/ejhf.2880. Epub 2023 May 8. Eur J Heart Fail. 2023. PMID: 37114368 No abstract available.

Use of and association between heart failure pharmacological treatments and outcomes in obese versus non-obese patients with heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry.
Cappelletto C, Stolfo D, Orsini N, Benson L, Rodolico D, Rosano GMC, Dahlström U, Sinagra G, Lund LH, Savarese G. Cappelletto C, et al. Eur J Heart Fail. 2023 May;25(5):698-710. doi: 10.1002/ejhf.2795. Epub 2023 Mar 6. Eur J Heart Fail. 2023. PMID: 36781199

1. Cappelletto C, Stolfo D, Orsini N, Benson L, Rodolico D, Rosano GMC, et al. Use of and association between heart failure pharmacological treatments and outcomes in obese versus non-obese patients with heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry. Eur J Heart Fail. 2023;25:698-710.
1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24:4-131.
1. Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776-85.
1. D'Amario D, Rodolico D, Rosano GMC, Dahlström U, Crea F, Lund LH, et al. Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry. Eur J Heart Fail. 2022;24:871-84.